Skip to content
ATLAS PREP HQ
Healing

BPC-157

Body Protection Compound-157, a synthetic 15-amino-acid gastric peptide analogue

Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

Preclinical Evidence

Route

Subcutaneous in the community reference

Common format

10 mg vial

Research focus

tendon and ligament repair

Evidence level

Preclinical Evidence

Typical cycle

4–8 weeks

Healing research motifHealing

BPC-157 in 30 seconds

Atlas Fast Read

What it is

Body Protection Compound-157, a synthetic 15-amino-acid gastric peptide analogue

Why people care

Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

The central gap is the absence of robust controlled human trials despite extensive animal literature. Human pharmacokinetics, bioavailability by route, dose-response, carcinogenesis/angiogenesis implications, long-term safety, and product identity/purity all remain unresolved.

Bottom line

BPC-157 may be one of the most compelling examples of the gap between peptide popularity and evidence quality.

Overview

What is BPC-157?

BPC-157 is body Protection Compound-157, a synthetic 15-amino-acid gastric peptide analogue. Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

BPC-157 emerged from Croatian gastric-protection research in the 1990s and 2000s. It became popular in sports-recovery communities long before controlled human efficacy trials were available.

Mechanism

How it works

Proposed mechanisms include modulation of nitric-oxide signaling, VEGF and other growth-factor pathways, angiogenesis, fibroblast activity, and cytoprotective signaling. Most mechanistic work is from cell and animal models.

Research areas

tendon and ligament repairmuscle injurygastrointestinal protectionangiogenesis/inflammation

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Meaningful controlled human efficacy evidence is absent. A few small or observational human reports have appeared, but they do not establish efficacy for tendon, ligament, muscle, gut, or systemic healing claims.

Preclinical evidence

A large preclinical literature in rodents reports effects on tendon, ligament, muscle, bone, nerve, gastrointestinal injury, angiogenesis, and nitric-oxide signaling. The consistency of animal findings is the main reason the compound attracts interest, but the absence of comparable human trials is a major limitation.

Knowledge gaps

The central gap is the absence of robust controlled human trials despite extensive animal literature. Human pharmacokinetics, bioavailability by route, dose-response, carcinogenesis/angiogenesis implications, long-term safety, and product identity/purity all remain unresolved.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community reference: 200–600 mcg/day with gradual titration. community sources' 2026 dosage guide describes roughly 250–500 mcg/day as the most common community range, with higher short-term ranges discussed for acute injury. There is no clinically validated human dose.

Frequency

Once daily in the community protocol.

Timing

No evidence-based time-of-day requirement.

Route

Subcutaneous in the community reference; human efficacy for any route remains unestablished.

Cycle length

4–8 weeks

Reconstitution

Community reference: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C, protected from light, avoid freeze-thaw.

Monitoring

There is no validated biomarker-monitoring protocol. Track injury symptoms/function, adverse effects, CBC/CMP when clinically appropriate, and avoid using symptom improvement to delay diagnosis of structural injury.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Controlled human safety data are limited. Possible issues include injection-site reactions, headache, nausea, dizziness, fatigue and hypersensitivity. Because several proposed mechanisms involve angiogenesis or tissue-growth signaling, long-term systemic effects are uncertain.

Contraindications

No validated human contraindication profile exists. Pregnancy/breastfeeding, active malignancy, unexplained masses, major bleeding disorders or serious systemic illness warrant avoidance outside formal research/medical oversight.

Interactions

Formal interaction studies are lacking. Use with anticoagulants/antiplatelet drugs, growth-factor therapies, immunomodulators or other experimental repair peptides creates unknown additive risks.

Stacks

Common stacks

BPC-157 + TB-500

Common recovery pairing that combines BPC-157's preclinical cytoprotective/angiogenic rationale with thymosin-beta-4-related cell-migration and repair biology.

Preclinical/community use; no controlled human efficacy trial of the combination.

BPC-157 + GHK-Cu

Discussed for tissue/skin repair because the compounds act through different repair and matrix-remodeling pathways.

No controlled human evidence for the injectable combination.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

BPC-157 may be one of the most compelling examples of the gap between peptide popularity and evidence quality. The animal healing data are extensive, but meaningful controlled human evidence is still missing. Atlas rates it preclinical: high scientific interest, low certainty for real-world human outcomes.

More in Healing

Healing

Ara-290

Innate-repair-receptor peptide research centered on inflammation, tissue protection, and neuropathy.

Read guide

Healing

BPC-157 + TB-500

Combination research pairing BPC-157 and TB-500 for tissue repair, wound healing, and musculoskeletal recovery.

Read guide

Healing

Cartalax

Short peptide bioregulator studied for connective-tissue support and fibroblast-related activity.

Read guide